Original Source(s)
Related Content
FDA expands essential thrombocythemia care
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
-
2 min
FDA approves first therapy for warm autoimmune hemolytic anemia
The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.
August 25, 2026
-
3 min
Newborn variants may flag childhood cancer predisposition
Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.
August 28, 2026
-
4 min